Replicate Bioscience

Replicate Bioscience is a private, pre-revenue biotech firm developing a proprietary self-replicating RNA (srRNA) platform. The technology is engineered to use the cell's own machinery to repeatedly produce therapeutic RNA, leading to significantly higher and more durable protein expression than standard mRNA. The company is advancing a pipeline of srRNA candidates across infectious disease, oncology, and autoimmune indications, positioning itself to address limitations of current RNA therapeutics. Recent milestones include grant funding for vaccine development and key leadership appointments.

Next-generation self-replicating RNA (srRNA) vectors derived from alphavirus. Once inside cells, the srRNA encodes a replicase that drives amplification of the therapeutic RNA, leading to high-level, durable protein expression.

Replicate operates in the highly competitive next-generation RNA therapeutics space. Key competitors include companies developing self-amplifying RNA (saRNA) like Arcturus Therapeutics and Gritstone bio, as well as giants like Moderna and BioNTech advancing their own mRNA enhancements. Differentiation will hinge on demonstrating superior durability, potency, and tolerability in clinical settings.